This response letter addresses observations from a warning letter issued by the FDA to XYZ labs on August 15, 2017. It summarizes 3 observations: 1) Failure to properly clean and maintain equipment led to residue issues. Corrective actions included improved training. 2) Failure to follow written recall procedures for a defective product batch until prompted. Personnel were replaced and record handling revised. 3) Failure to thoroughly investigate a customer complaint about a failed dissolution test. Root cause was campaign manufacturing and corrective actions included improved cleaning and training.